Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 1, pp. 47-58
Open Access | Times Cited: 325

Showing 1-25 of 325 citing articles:

Advances in diagnosis and treatment of bladder cancer
Antonio López-Beltrán, Michael S. Cookson, Brendan J. Guercio, et al.
BMJ (2024), pp. e076743-e076743
Open Access | Times Cited: 135
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
Giorgio Bogani, Bradley J. Monk, Matthew A. Powell, et al.
Annals of Oncology (2024) Vol. 35, Iss. 5, pp. 414-428
Closed Access | Times Cited: 35
HER2-targeted therapies in cancer: a systematic review
Kunrui Zhu, Xinyi Yang, Hebei Tai, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 27
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. 2446-2455
Open Access | Times Cited: 25
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. 707-719
Closed Access | Times Cited: 18
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature
Francesco Claps, Arianna Biasatti, Luca Di Gianfrancesco, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 15, pp. 4349-4349
Open Access | Times Cited: 17
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1147-1162
Closed Access | Times Cited: 15
Cervical Cancer
Krishnansu S. Tewari
New England Journal of Medicine (2025) Vol. 392, Iss. 1, pp. 56-71
Closed Access | Times Cited: 2
Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers
Xin Wang, Anna Saborowski, Gonzalo Sapisochín, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 2
Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review
Lu Wang, Shidi Wen, Wenjia Zhu, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Alessandro D. Santin, Bradley R. Corr, Alexander I. Spira, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 29, pp. 3421-3429
Closed Access | Times Cited: 12
Cervical cancer: a new era
Giuseppe Caruso, Matthew K. Wagar, Heng‐Cheng Hsu, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 12, pp. 1946-1970
Closed Access | Times Cited: 12
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
Timothy P. DiPeri, Kurt W. Evans, Bailiang Wang, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 828-845
Open Access | Times Cited: 11
2023 FIGO staging system for endometrial cancer: The evolution of the revolution
David K. Gaffney, Xavier Matías‐Guiu, David G. Mutch, et al.
Gynecologic Oncology (2024) Vol. 184, pp. 245-253
Closed Access | Times Cited: 11
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 11
Evolving standards and future directions for systemic therapies in cervical cancer
Daniel Jia Ming Ang, Jack Junjie Chan
Journal of Gynecologic Oncology (2024) Vol. 35, Iss. 2
Open Access | Times Cited: 10
Recent Therapeutic Advances in Gynecologic Oncology: A Review
Elise Wilson, Ramez N. Eskander, Pratibha Binder
Cancers (2024) Vol. 16, Iss. 4, pp. 770-770
Open Access | Times Cited: 10
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
C. Benedikt Westphalen, Diogo Martins-Branco, Juliana Rodrigues Beal, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 936-953
Open Access | Times Cited: 9
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors
Yoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, et al.
Nature Medicine (2024)
Open Access | Times Cited: 9
HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls
Huina Zhang, Brian S. Finkelman, Mark Ettel, et al.
Histopathology (2024) Vol. 85, Iss. 1, pp. 3-19
Closed Access | Times Cited: 8
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
Nina Eißler, Renske Altena, Ali Alhuseinalkhudhur, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1088-1088
Open Access | Times Cited: 8
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Jia Liu, M. Farrow, Lesley Seymour, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Management of nausea and vomiting induced by antibody–drug conjugates
Jawhara Farhat, Hitomi Sakai, Junji Tsurutani
Breast Cancer (2025)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top